Ishikawa细胞系

Ishikawa/Ishikawa细胞系/Ishikawa细胞株/Ishikawa人子宫内膜癌细胞

Cell line name Ishikawa

Synonyms ISHIKAWA; ISHI

Accession CVCL_2529

Resource Identification Initiative To cite this cell line use: Ishikawa (RRID:CVCL_2529)

Comments Part of: ENCODE project common cell types; tier 3.

Population: Japanese.

Doubling time: 36 hours (Note=At 9th passage), 29 hours (Note=At 40th passage), 27 hours (Note=At 50th passage) (DOI=10.1007/978-4-431-53981-0_2); 35.14 +- 2.68 hours (PubMed=23255909).

Omics: Array-based CGH.

Omics: Chromatin accessibility by ATAC-seq.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Misspelling: Ischikawaa; Note=Occasionally.

Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.

Sequence variations

Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).

Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).

Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).

Mutation; HGNC; 9588; PTEN; Simple; p.Ser302fs*4 (c.906delC); Zygosity=Heterozygous (PubMed=20944090).

Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).

Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=20944090).

Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).

Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=15901131).

Disease Endometrial adenocarcinoma (NCIt: C7359)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_W441 (EIIL) CVCL_N296 (IK-6) CVCL_9996 (IK-90)

CVCL_IR24 (ISH/DDP) CVCL_6543 (Ishikawa (Heraklio) 02 ER-) CVCL_8783 (Ishikawa (London) 02 ER+)

CVCL_W420 (Ishikawa 1-A-12) CVCL_W421 (Ishikawa 1-A-9) CVCL_W422 (Ishikawa 1-C-10)

CVCL_W423 (Ishikawa 1-D-9) CVCL_W424 (Ishikawa 1-E-8) CVCL_W425 (Ishikawa 1-F-6)

CVCL_W426 (Ishikawa 1-H-6) CVCL_W427 (Ishikawa 2-B-12) CVCL_W428 (Ishikawa 2-C-3)

CVCL_W429 (Ishikawa 2-C-7) CVCL_W430 (Ishikawa 2-E-7) CVCL_W431 (Ishikawa 2-F-4)

CVCL_W432 (Ishikawa 3-D-7) CVCL_W433 (Ishikawa 3-D-9) CVCL_D199 (Ishikawa 3-H-12)

CVCL_W434 (Ishikawa 3-H-3) CVCL_W435 (Ishikawa 3-H-4) CVCL_W436 (Ishikawa 3-H-7)

CVCL_C9CC (ISHIKAWA-Luc) CVCL_IJ14 (Ishikawa-RP)

Sex of cell Female

Age at sampling 39Y

Category Cancer cell line

STR profile Source(s): ECACC=99040201; PubMed=25877200

 

Markers:

Amelogenin X

CSF1PO 11,12

D2S1338 20

D3S1358 15,17

D5S818 10,11

D7S820 9,10

D8S1179 12,16

D13S317 9,12

D16S539 9

D18S51 13,19

D19S433 12.2,14

D21S11 28

FGA 21

Penta D 10,11

Penta E 11,19

TH01 9,10

TPOX 8

vWA 14,17

 

Run an STR similarity search on this cell line

PubMed=12703541; DOI=10.1111/j.1749-0774.2002.tb00105.x

Nishida M.

The Ishikawa cells from birth to the present.

Hum. Cell 15:104-117(2002)

 

DOI=10.1007/978-4-431-53981-0_2

Nishida M.

Ishikawa cells: opening of in vitro hormone research on endometrial carcinoma.

(In book chapter) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.35-58; Springer; Tokyo; Japan (2003)

 

PubMed=15053063

Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.

Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines.

Eur. J. Gynaecol. Oncol. 25:55-60(2004)

 

PubMed=15901131; DOI=10.1016/j.prp.2005.01.002

Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.

Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines.

Pathol. Res. Pract. 201:109-115(2005)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=20218740; DOI=10.1177/153303461000900207; PMCID=PMC5120669

Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R., Zhang W.

Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.

Technol. Cancer Res. Treat. 9:179-189(2010)

 

PubMed=20944090; DOI=10.1126/scitranslmed.3001538

Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R., Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A., Lord C.J., Ashworth A., Reis-Filho J.S.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010)

 

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677

Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Gynecol. Oncol. 127:241-248(2012)

 

PubMed=23255909; DOI=10.3892/ol.2012.975; PMCID=PMC3525505

Zhao S.-J., Li G.-X., Yang L., Li L., Li H.-Y.

Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.

Oncol. Lett. 5:139-144(2013)

 

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S.,  T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)